- 注册
- 2002-10-07
- 消息
- 402,229
- 荣誉分数
- 76
- 声望点数
- 0
<HTML>CHICAGO, Oct. 18 /PRNewswire/ -- Zacks.com releases another list of stocks that are currently members of the coveted Zacks #1 Ranked list which has produced an average annual return of 34% since inception in 1980. Among the #1 ranked stocks are the following companies: Cubist Pharmaceuticals (Nasdaq: CBST) and Copart Inc. (Nasdaq: CPRT). Further they announced #2 Rankings (Buy) on two other widely held stocks: IDEC Pharmaceuticals (Nasdaq: IDPH) and Novell (Nasdaq: NOVL). To see the full Zacks #1 Ranked list or the rank for any other stock then visit http://www.zacksrank16.zacks.com (Photo: http://www.newscom.com/cgi-bin/prnh/20010924/CGM015LOGO )
Here is a synopsis of why these stocks were added to the Zacks #1 Ranked List:
Cubist Pharmaceuticals (Nasdaq: CBST): Cubist has been upgrading earnings estimates and has a strong outlook going forward. The company just reported positive results in Phase III trials on its drug, Cidecin. The drug is likely to create a market that will generate $300-400 million in sales for the company!
Copart Inc. (Nasdaq: CPRI): Copart auctions salvaged cars and is certainly able to salvage profit in this environment. The company upgraded earnings estimates for 2002 and 2003 when it reported a 34% revenue increase and a 53% EPS increase in this past quarter. Copart is in a highly predictable, non- cyclical market niche and continues to increase market share and return on equity.
Here is a synopsis of why these stocks have a Zacks Rank of 2 (Buy):
IDEC Pharmaceuticals (Nasdaq: IDPH): Analyst earnings estimates for IDEC have been steadily increasing of late for 2001 and 2002. The company's drugs Rituxin and Zevalin are generating excellent and unforeseen levels of sales. An FDA Advisory Committee recommended the drug Zevalin whose sales should increase from $2 million in 2001 to $205 million in 2005.
Novell (Nasdaq: NOVL): The most recent expert recommendations on Novell point to a profit in 2002 compared with previous projections of a loss. The company's stocks will benefit from an extended stock repurchasing program and it will benefit from massive demand for training classes in its new platform it is about to deliver to the marketplace.
</HTML>
Here is a synopsis of why these stocks were added to the Zacks #1 Ranked List:
Cubist Pharmaceuticals (Nasdaq: CBST): Cubist has been upgrading earnings estimates and has a strong outlook going forward. The company just reported positive results in Phase III trials on its drug, Cidecin. The drug is likely to create a market that will generate $300-400 million in sales for the company!
Copart Inc. (Nasdaq: CPRI): Copart auctions salvaged cars and is certainly able to salvage profit in this environment. The company upgraded earnings estimates for 2002 and 2003 when it reported a 34% revenue increase and a 53% EPS increase in this past quarter. Copart is in a highly predictable, non- cyclical market niche and continues to increase market share and return on equity.
Here is a synopsis of why these stocks have a Zacks Rank of 2 (Buy):
IDEC Pharmaceuticals (Nasdaq: IDPH): Analyst earnings estimates for IDEC have been steadily increasing of late for 2001 and 2002. The company's drugs Rituxin and Zevalin are generating excellent and unforeseen levels of sales. An FDA Advisory Committee recommended the drug Zevalin whose sales should increase from $2 million in 2001 to $205 million in 2005.
Novell (Nasdaq: NOVL): The most recent expert recommendations on Novell point to a profit in 2002 compared with previous projections of a loss. The company's stocks will benefit from an extended stock repurchasing program and it will benefit from massive demand for training classes in its new platform it is about to deliver to the marketplace.
</HTML>
